News
Takeda schließt Verkauf ausgewählter OTC- und nicht zum Kerngeschäft gehörender Assets an Acino ab
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) meldete heute den Abschluss des bereits angekündigten Verkaufs eines Portfolios ausgewählter, frei verkäuflicher
Premier Inc. Survey Finds 86 Percent of Health Systems Are Concerned About Personal Protective Equipment Shortages Due to Coronavirus
Premier Inc. (NASDAQ: PINC) today released survey results finding that 86 percent of U.S. hospitals and health systems are concerned about their supply of face masks and other personal protective
Heat Biologics mit +210% in 2 Tagen – dank Corona!
Als einer der meistdiskutierten Werte in unserem Live Chat macht die Aktie von Heat Biologics (WKN: A2JB4Y) aktuell mit einem Höhenflug von +210% innerhalb von nur zwei Tagen auf sich aufmerksam
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Takeda vereinbart Veräußerung ausgewählter kernferner und OTC-Aktiva in Lateinamerika an Hypera Pharma für 825 Mio. USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) („Takeda“) hat eine Vereinbarung darüber geschlossen, ein Portfolio ausgewählter kernferner Produkte ausschließlich für den
Agilent and Visiopharm Co-promote Advanced Digital Precision Pathology Solutions
Agilent Technologies Inc. (NYSE: A) and Visiopharm today announced that they have entered a co-marketing agreement. The announcement is happening at the USCAP 109th Annual Meeting being held
Sangamo Therapeutics Announces Participation at Upcoming Investor Conferences
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the following investor conferences:
-
Cowen 40th Annual Health Care
Waters Drives Materials Sciences Innovation Forward at Pittcon 2020 with New Instrument Introductions
Waters Corporation (NYSE:WAT) today introduced new products that bring greater productivity and efficiency to materials science research. The new Discovery™ X3 Differential Scanning Calorimeter
Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat, today announced that it has
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Completes Sale of Select OTC and Non-Core Assets to Acino
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin
Takeda Agrees to Divest Select OTC and Non-Core Assets in Latin America to Hypera Pharma for $825 Million USD
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin